Polyglutamine-containing proteins in neuropsychiatric disorders
CA 2350557 A1 · Owner: Joober, Ridha · Inventors: Rouleau, Guy; Joober, Ridha
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to dis-, eases caused by CAG repeat expansions. More particularly the present invention re-, lates to neuropsychiatric diseases caused by CAG repeat expansions and even more particularly to schizophrenia and major depression. In particular, the present invention relates to the identification of at least one protein containing polyglutamine arrays, which acts as a marker for the pathogenesis of a neuropsychiatric disorder and more particularly for schizophrenia and major depression. The present invention further relates to diagnosis and treatment of neuropsychiatric disorders linked to polyglutamine tracts-containing proteins. The present invention further …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 3, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 3, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 3, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.